Abstract
Selegiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B). Selegiline is looked upon as a putative progression of Parkinson's disease (PD) delaying compound due to its in preclinical research proven neuroprotective modes of action. Xilopar® is a new formulation of selegiline, which facilitates absorption in the mouth and thus avoids hepatic first-pass metabolism. Intake of 1.25 mg Xilopar® provides similar pharmacokinetic plasma behaviour corresponding to oral administration of 10 mg conventional selegiline. This observational trial evaluated the efficacy, safety and tolerability of Xilopar® in the daily practice. Motor symptoms and fluctuations of PD patients improved after 3 months of initial treatment with Xilopar® or switch from selegiline to Xilopar®. Both treatment strategies enabled a reduction of the daily oral levodopa intake (initial treatment with Xilopar®: 21%; 143 ± 115 [mean ± SD] mg/daily; pre-treatment with selegiline: 17%; 98 ± 40 mg/daily). There were no safety or tolerability problems. The results of this observational trial confirm the clinical efficacy, tolerability and safety of Xilopar*, respectively conventional selegiline formulations in the treatment of PD.
| Translated title of the contribution | A new galenic formulation of selegiline (Xilopar®) in the treatment of Parkinson disease |
|---|---|
| Original language | German |
| Pages (from-to) | 347-352 |
| Number of pages | 6 |
| Journal | Aktuelle Neurologie |
| Volume | 31 |
| Issue number | 7 |
| DOIs | |
| State | Published - Sep 2004 |
| Externally published | Yes |